By Ludwig Burger
FRANKFURT Thu Apr 3, 2014 11:39am EDT
<span id="articleText"><span id="midArticle_start"/> FRANKFURT (Reuters) - Dialysis specialist Fresenius Medical Care said it expected sales to almost double to $28 billion by 2020, driven by growing patient numbers and as it aims to widen its services to medical fields related to kidney failure.
<span id="midArticle_1"/>The target is equivalent to an average annual increase of about 10 percent from $14.6 billion last year, the world's largest dialysis company said in presentation slides shown on its website on Thursday as part of its capital markets day.
<span id="midArticle_2"/>The shares extended gains on the news and traded 3.5 percent higher at 1507 GMT.
<span id="midArticle_3"/>The number of global dialysis patients is set to grow by 6.3 percent per year through 2020, after a 6.8 percent average annual gains over the past 13 years, FMC estimates.
<span id="midArticle_4"/>FMC is also banking on medical insurers to increasingly pay it for coordinating a range of treatments beyond dialysis.
<span id="midArticle_5"/>U.S. state-run insurer Medicare has started switching to no longer paying for individual services and drugs and instead to making lump-sum reimbursements per dialysis session, creating incentives for clinic operators to use drugs sparingly and renegotiate procurement prices.
<span id="midArticle_6"/>FMC expects private insurers in the United States to expand such models to include the treatment of conditions that are linked to dialysis, such as infections of the injection site.
<span id="midArticle_7"/>FMC believes it is better placed than its smaller rivals to adapt to such systems.
<span id="midArticle_8"/>Chief Executive Rice Powell said coordinating patient care could account for 18 percent of sales by 2020, up from 3 percent currently.
<span id="midArticle_9"/>Kidney failure is often a result of medical conditions that result from sedentary lifestyles in industrialized countries such as diabetes or high blood pressure.
<span id="midArticle_10"/>While about two-thirds of FMC's revenue comes from North America, the company is seeing faster growth in emerging markets where western lifestyles are taking hold and rising wealth is driving an increase in insurance coverage.
<span id="midArticle_11"/>FMC said on Thursday it expected about 4.5 percent growth in the overall number of dialysis patients in North America, 5.2 percent growth in Latin America and 8.4 percent in the Asia-Pacific region until 2020.
<span id="midArticle_12"/>(Reporting by Ludwig Burger; Editing by Christoph Steitz an Victoria Bryan)
<span id="midArticle_13"/>
FRANKFURT Thu Apr 3, 2014 11:39am EDT
<span id="articleText"><span id="midArticle_start"/> FRANKFURT (Reuters) - Dialysis specialist Fresenius Medical Care said it expected sales to almost double to $28 billion by 2020, driven by growing patient numbers and as it aims to widen its services to medical fields related to kidney failure.
<span id="midArticle_1"/>The target is equivalent to an average annual increase of about 10 percent from $14.6 billion last year, the world's largest dialysis company said in presentation slides shown on its website on Thursday as part of its capital markets day.
<span id="midArticle_2"/>The shares extended gains on the news and traded 3.5 percent higher at 1507 GMT.
<span id="midArticle_3"/>The number of global dialysis patients is set to grow by 6.3 percent per year through 2020, after a 6.8 percent average annual gains over the past 13 years, FMC estimates.
<span id="midArticle_4"/>FMC is also banking on medical insurers to increasingly pay it for coordinating a range of treatments beyond dialysis.
<span id="midArticle_5"/>U.S. state-run insurer Medicare has started switching to no longer paying for individual services and drugs and instead to making lump-sum reimbursements per dialysis session, creating incentives for clinic operators to use drugs sparingly and renegotiate procurement prices.
<span id="midArticle_6"/>FMC expects private insurers in the United States to expand such models to include the treatment of conditions that are linked to dialysis, such as infections of the injection site.
<span id="midArticle_7"/>FMC believes it is better placed than its smaller rivals to adapt to such systems.
<span id="midArticle_8"/>Chief Executive Rice Powell said coordinating patient care could account for 18 percent of sales by 2020, up from 3 percent currently.
<span id="midArticle_9"/>Kidney failure is often a result of medical conditions that result from sedentary lifestyles in industrialized countries such as diabetes or high blood pressure.
<span id="midArticle_10"/>While about two-thirds of FMC's revenue comes from North America, the company is seeing faster growth in emerging markets where western lifestyles are taking hold and rising wealth is driving an increase in insurance coverage.
<span id="midArticle_11"/>FMC said on Thursday it expected about 4.5 percent growth in the overall number of dialysis patients in North America, 5.2 percent growth in Latin America and 8.4 percent in the Asia-Pacific region until 2020.
<span id="midArticle_12"/>(Reporting by Ludwig Burger; Editing by Christoph Steitz an Victoria Bryan)
<span id="midArticle_13"/>
- Link this
- Share this
- Digg this
- Reprints
via Smart Health Shop Forum http://ift.tt/1ovcBdn
No comments:
Post a Comment